Literature DB >> 29082918

The unique structural and functional features of CXCL12.

Rik Janssens1, Sofie Struyf1, Paul Proost2.   

Abstract

The CXC chemokine CXCL12 is an important factor in physiological and pathological processes, including embryogenesis, hematopoiesis, angiogenesis and inflammation, because it activates and/or induces migration of hematopoietic progenitor and stem cells, endothelial cells and most leukocytes. Therefore, CXCL12 activity is tightly regulated at multiple levels. CXCL12 has the unique property of existing in six splice variants in humans, each having a specific tissue distribution and in vivo activity. Controlled splice variant transcription and mRNA stability determine the CXCL12 expression profile. CXCL12 fulfills its functions in homeostatic and pathological conditions by interacting with its receptors CXC chemokine receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3) and by binding to glycosaminoglycans (GAGs) in tissues and on the endothelium to allow a proper presentation to passing leukocytes. Homodimerizaton and heterodimerization of CXCL12 and its receptors can alter their signaling activity, as exemplified by the synergy between CXCL12 and other chemokines in leukocyte migration assays. Receptor binding may also initiate CXCL12 internalization and its subsequent removal from the environment. Furthermore, CXCL12 activity is regulated by posttranslational modifications. Proteolytic removal of NH2- or COOH-terminal amino acids, citrullination of arginine residues by peptidyl arginine deiminases or nitration of tyrosine residues reduce CXCL12 activity. This review summarizes the interactions of CXCL12 with the cellular environment and discusses the different levels of CXCL12 activity regulation.

Entities:  

Keywords:  ACKR3; CXCL12; CXCR4; chemokine; regulation

Mesh:

Substances:

Year:  2017        PMID: 29082918      PMCID: PMC6052832          DOI: 10.1038/cmi.2017.107

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  135 in total

1.  Proteomic method identifies proteins nitrated in vivo during inflammatory challenge.

Authors:  K S Aulak; M Miyagi; L Yan; K A West; D Massillon; J W Crabb; D J Stuehr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  Chemokines integrate JAK/STAT and G-protein pathways during chemotaxis and calcium flux responses.

Authors:  Silvia F Soriano; Antonio Serrano; Patricia Hernanz-Falcón; Ana Martín de Ana; María Monterrubio; Carlos Martínez; J Miguel Rodríguez-Frade; Mario Mellado
Journal:  Eur J Immunol       Date:  2003-05       Impact factor: 5.532

3.  The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.

Authors:  Karl Balabanian; Bernard Lagane; Simona Infantino; Ken Y C Chow; Julie Harriague; Barbara Moepps; Fernando Arenzana-Seisdedos; Marcus Thelen; Françoise Bachelerie
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

Review 4.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines.

Authors:  T M Handel; Z Johnson; S E Crown; E K Lau; A E Proudfoot
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

5.  Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.

Authors:  A M Lambeir; P Proost; C Durinx; G Bal; K Senten; K Augustyns; S Scharpé; J Van Damme; I De Meester
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

6.  Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

Authors:  G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

7.  The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.

Authors:  Veysel Odemis; Jana Lipfert; Robert Kraft; Peter Hajek; Getu Abraham; Kirsten Hattermann; Rolf Mentlein; Jürgen Engele
Journal:  Glia       Date:  2011-11-14       Impact factor: 7.452

8.  Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes.

Authors:  Rik Janssens; Anneleen Mortier; Daiane Boff; Pieter Ruytinx; Mieke Gouwy; Bo Vantilt; Olav Larsen; Viktorija Daugvilaite; Mette M Rosenkilde; Marc Parmentier; Sam Noppen; Sandra Liekens; Jo Van Damme; Sofie Struyf; Mauro M Teixeira; Flávio A Amaral; Paul Proost
Journal:  Biochem Pharmacol       Date:  2017-03-18       Impact factor: 5.858

9.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7.

Authors:  Frederic Sierro; Christine Biben; Laura Martínez-Muñoz; Mario Mellado; Richard M Ransohoff; Meizhang Li; Blanche Woehl; Helen Leung; Joanna Groom; Marcel Batten; Richard P Harvey; Carlos Martínez-A; Charles R Mackay; Fabienne Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

10.  CXCR7 functions as a scavenger for CXCL12 and CXCL11.

Authors:  Ulrike Naumann; Elisabetta Cameroni; Monika Pruenster; Harsha Mahabaleshwar; Erez Raz; Hans-Günter Zerwes; Antal Rot; Marcus Thelen
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

View more
  81 in total

Review 1.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

2.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  The involvement of bioactive factors in the self-renewal and stemness maintenance of spermatogonial stem cells.

Authors:  Guoqing Yang; Yuqing He; Hao Yang
Journal:  Mol Cell Biochem       Date:  2021-01-18       Impact factor: 3.396

4.  Chemokines: the past, the present and the future.

Authors:  Peng Tang; Ji Ming Wang
Journal:  Cell Mol Immunol       Date:  2018-03-26       Impact factor: 11.530

Review 5.  Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.

Authors:  Philip M Murphy; Lauren Heusinkveld
Journal:  Cytokine       Date:  2018-02-15       Impact factor: 3.861

6.  SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo.

Authors:  Chi-Neu Tsai; Shu-Chuan Yu; Chao-Wei Lee; Jong-Hwei Su Pang; Chun-Hsin Wu; Sey-En Lin; Yi-Hsiu Chung; Chia-Lung Tsai; Sen-Yung Hsieh; Ming-Chin Yu
Journal:  Oncogene       Date:  2020-05-13       Impact factor: 9.867

Review 7.  What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.

Authors:  Ahmed M Elmansi; Mohamed E Awad; Nada H Eisa; Dmitry Kondrikov; Khaled A Hussein; Alexandra Aguilar-Pérez; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Sadanand Fulzele; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Brian F Volkman; William D Hill
Journal:  Pharmacol Ther       Date:  2019-02-10       Impact factor: 12.310

8.  A promising effect of zerumbone with improved anti-tumor-promoting inflammation activity of miR-34a in colorectal cancer cell lines.

Authors:  Razieh Dehghan; Rezvan Najafi; Farid Azizi Jalilian; Massoud Saidijam; Zahra Radaei; Alireza Zamani; Razieh Ezati; Farzaneh Asna-Ashari; Razieh Amini
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

9.  Functional mimetic of the G-protein coupled receptor CXCR4 on a soluble antibody scaffold.

Authors:  Adem C Koksal; Meghan E Pennini; Marcello Marelli; Xiaodong Xiao; William F Dall'Acqua
Journal:  MAbs       Date:  2019-04-16       Impact factor: 5.857

Review 10.  Nature-Derived Peptides: A Growing Niche for GPCR Ligand Discovery.

Authors:  Edin Muratspahić; Michael Freissmuth; Christian W Gruber
Journal:  Trends Pharmacol Sci       Date:  2019-04-05       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.